跳至主要内容
临床试验/CTRI/2024/10/074674
CTRI/2024/10/074674尚未招募不适用

A Clinical Study on the Efficacy of Mahaswasari Loham in Tamaka Swasa with special reference to Bronchial Asthma

Dr Kummari Nikhitha1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年10月14日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
30
试验地点
1
主要终点
To reduce the frequency of episodes of Shortness of breath

研究概览

简要总结

Bronchial Asthma is a major non-communicable disease (NCD) & most common chronic obstructive lung disease affecting all age groups, which is characterized by chronic airway inflammation and increased airway hyper-responsiveness leading to symptoms of wheeze, cough, chest tightness and dyspnea.   It is characterized functionally by the presence of airflow obstruction which is variable over short periods of time or is reversible with treatment. Asthma is included in the WHO Global action plan for the Prevention and Control of NCDs and the United Nations 2030 Agenda for Sustainable Development and to make progress towards Universal Health coverage.  Bronchial Asthma is correlated with “Tamaka Swasa” based on the clinical features described in Ayurvedic Samhitas. â€œSwasati anena iti Swasah”(Shabda Kalpa Druma). In general, the word Swasa denotes respiration during physiological and pathologic conditions with normal and abnormal breathing pattern.***‘Tamaka swasa’***is one among the five types of SWASA ROGA, it is described as Vata Kaphaja vikara mainly originating from Pittasthana and then manifested through Pranavaha Srotas.  Due to nidanas (causative factors) Vata and Kapha gets prakopa in the Uras leading to vitiation of Pranavaha, Annavaha, Udakavaha srotas, later the obstructed Vayu travels in Pratiloma gati (reverse direction) and produces signs and symptoms of *Tamaka swasa.*During initial stages it is Sadhya (curable) and later it turns into Yapya vyadhi (palliable) if not treated properly.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • 1.Who are willing to participate in the study and agree for the consent sign 2.symptoms exacerbations cough, wheeze, dyspnea greater than a week 3.Mild persistant cases of asthma of duration more than 6months 4.Night symptoms twice per month but less than twice per week 5.FEVI greater than 80% 6.spo2 greater than 92% 7.Non smokers.

排除标准

  • 1.Moderate and severe persistent asthma 2.Asthma due to other systemic origin 3.suffering from diabetes,cardiac asthma, status asthmatics,CVDs, autoimmune disorders.
  • 4.HIV positive cases,pregnant women, lactating mothers 5.patients who need salbutamol inhaler daily 6.dyspnea due to other diseases like COPD, bronchiectasis, pulmonary tuberculosis, interstitial lung disease, occupational lung disease, malignancies.

结局指标

主要结局

To reduce the frequency of episodes of Shortness of breath

时间窗: 60 days

次要结局

  • to reduce the signs and symptoms of bronchial Asthma(60 days)

研究者

发起方
Dr Kummari Nikhitha
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Kummari Nikhitha

Dr. BRKR Govt Ayurvedic college & Hospital

研究点 (1)

Loading locations...

相似试验